Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Eating a Handful of Peanuts Could Change Your Blood in a Surprising Way, Study Finds (opens in a new tab)

scitechdaily.com · 2026-10-30

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 2 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredResearchers combined a six-month dietary experiment with data from a long-term population study involving more than 27,000 people to study peanut consumption, blood lipids, and diabetes risk.View evidenceHide evidence

As statedmore than 27,000 people

Why this verdict

The profile supports integration of the ARISTOTLE 6-month dietary intervention with EPIC-Potsdam prospective population/case-cohort data to study peanut-related lipids and diabetes/CVD risk. However, the abstract-level profile does not verify the story’s stated total population size of “more than 27,000 people,” so the full claim cannot be confirmed at this evidence depth.

1

Study evidence

The ARISTOTLE randomized intervention modified 51 within-class fatty-acid sums in plasma, predominantly affecting VLCSFA-containing lipids and especially sphingolipids.51 within-class FA sums modified

“ARISTOTLE randomly assigned 63 healthy young adults to 25 g/d skin-roasted peanuts, 32 g/d peanut butter, or 32 g/d control butter with peanut oil for 6 mo.”
2

Study evidence

A peanut-derived lipidomic signature (PeLS), based on intervention-responsive lipids from ARISTOTLE, was associated with lower incident T2D risk in EPIC-Potsdam.HR 0.89 per 1-SD increase (95% CI: 0.80–0.99)

“We integrated data from the clinical trial ARISTOTLE and the prospective, population-based ... EPIC-Potsdam cohort.”
Claim 2 of 5Not coveredThe randomized controlled trial used 63 healthy adults ages 18 to 33 who consumed peanuts, peanut butter, or a control butter each day for six months.View evidenceHide evidence

As stated63 healthy adults ages 18 to 33; six months

Why this verdict

The profile supports a randomized 6-month ARISTOTLE trial with 63 healthy young adults assigned to skin-roasted peanuts, peanut butter, or control butter with peanut oil. The exact age range “18 to 33” is not present in the abstract-level profile, so that part is not verifiable at this depth.

1

Study evidence

The ARISTOTLE randomized intervention modified 51 within-class fatty-acid sums in plasma, predominantly affecting VLCSFA-containing lipids and especially sphingolipids.51 within-class FA sums modified

“ARISTOTLE randomly assigned 63 healthy young adults to 25 g/d skin-roasted peanuts, 32 g/d peanut butter, or 32 g/d control butter with peanut oil for 6 mo.”
Claim 3 of 5Not coveredPeanut consumption significantly increased certain very long-chain saturated fatty acids, especially C24:0 and C22:0, and produced a distinctive blood lipid pattern the authors called the 'Peanut Lipidomic Signature' (PeLS).View evidenceHide evidence

Why this verdict

The profile supports that the intervention modified 51 within-class fatty-acid sums, mainly VLCSFA-containing lipids, and that these intervention-responsive features were used to derive PeLS. But the abstract-level profile does not verify the specific direction “increased,” the statistical wording “significantly,” or the specific emphasis on C24:0 and C22:0.

1

Study evidence

The ARISTOTLE randomized intervention modified 51 within-class fatty-acid sums in plasma, predominantly affecting VLCSFA-containing lipids and especially sphingolipids.51 within-class FA sums modified

“ARISTOTLE randomly assigned 63 healthy young adults to 25 g/d skin-roasted peanuts, 32 g/d peanut butter, or 32 g/d control butter with peanut oil for 6 mo.”
2

Study evidence

A peanut-derived lipidomic signature (PeLS), based on intervention-responsive lipids from ARISTOTLE, was associated with lower incident T2D risk in EPIC-Potsdam.HR 0.89 per 1-SD increase (95% CI: 0.80–0.99)

“We integrated data from the clinical trial ARISTOTLE and the prospective, population-based ... EPIC-Potsdam cohort.”
Claim 4 of 5SupportedA handful of peanuts may leave a telltale signature in blood, and researchers linked that pattern to a lower risk of type 2 diabetes.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that a 6-month peanut intervention produced measurable plasma lipidomic changes and that a peanut lipidomic signature derived from those changes was associated with lower incident type 2 diabetes risk in EPIC-Potsdam. The story frames the disease-risk finding associationally and hedges with “may,” which is appropriate.

1

Study evidence

The ARISTOTLE randomized intervention modified 51 within-class fatty-acid sums in plasma, predominantly affecting VLCSFA-containing lipids and especially sphingolipids.51 within-class FA sums modified

“ARISTOTLE randomly assigned 63 healthy young adults to 25 g/d skin-roasted peanuts, 32 g/d peanut butter, or 32 g/d control butter with peanut oil for 6 mo.”
2

Study evidence

A peanut-derived lipidomic signature (PeLS), based on intervention-responsive lipids from ARISTOTLE, was associated with lower incident T2D risk in EPIC-Potsdam.HR 0.89 per 1-SD increase (95% CI: 0.80–0.99)

“We integrated data from the clinical trial ARISTOTLE and the prospective, population-based ... EPIC-Potsdam cohort.”
Claim 5 of 5SupportedIn the population study, the peanut lipid signature was associated with a lower risk of type 2 diabetes but not cardiovascular disease, and much of the diabetes association was statistically explained by body mass index.View evidenceHide evidence

As stated774 diabetes cases; 545 cardiovascular disease cases

Why this verdict

The substantive claim is supported: in EPIC-Potsdam, PeLS was associated with lower incident T2D risk, was not associated with CVD risk, and BMI was reported as a potential mediator with a large proportion explainable. The profile reports 774 T2D cases and 547 CVD cases; the story’s supplied magnitude field says 545 CVD cases, which does not match the profile. Also, the mediation result was hypothesis-generating, a caveat not reflected in the claim wording.

1

Study evidence

A peanut-derived lipidomic signature (PeLS), based on intervention-responsive lipids from ARISTOTLE, was associated with lower incident T2D risk in EPIC-Potsdam.HR 0.89 per 1-SD increase (95% CI: 0.80–0.99)

“We integrated data from the clinical trial ARISTOTLE and the prospective, population-based ... EPIC-Potsdam cohort.”
2

Study evidence

Higher baseline PeLS was associated with a modestly lower risk of incident type 2 diabetes in EPIC-Potsdam.HR 0.89 per 1-SD increase in PeLS (95% CI: 0.80–0.99)

“Multivariable Cox models were used to estimate hazard ratios (HRs) for PeLS and individual lipids with incident T2D and CVD.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • BMI was identified as a potential mediator of the PeLS–T2D association, with a reported proportion explainable of 89%, but the mediation analysis was hypothesis-generating.

    The story mentions statistical mediation by BMI, but it does not reflect the paper profile’s important caveat that the mediation analysis was hypothesis-generating and should be interpreted cautiously.

    From Prospective case-cohort; multivariable Cox models; secondary_analysis (mediation)

  • The randomized trial sample was small and limited to healthy young adults, which limits generalizability.

    The story reports the sample size and young adult sample but does not present the generalizability limitation as a caveat.

    From Randomized dietary intervention with pre–post plasma lipidomics; linear mixed-effects models; secondary_data: cross-stud

5 things the story did carry across
  • ARISTOTLE was a randomized 6-month dietary intervention in 63 healthy young adults assigned to peanuts, peanut butter, or control butter with peanut oil.
  • The intervention modified 51 within-class fatty-acid sums, predominantly VLCSFA-containing lipids and especially sphingolipids.
  • PeLS was constructed from intervention-responsive lipid features and applied to baseline plasma lipidomics in EPIC-Potsdam.
  • Higher PeLS was modestly associated with lower incident type 2 diabetes risk in EPIC-Potsdam.
  • PeLS was not associated with incident cardiovascular disease.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoIdentify plasma lipidome changes induced by peanut consumption in the ARISTOTLE randomized intervention.Randomized dietary intervention with pre–post plasma lipidomics; linear mixed-effects modelsExpand

In plain English

In the ARISTOTLE randomized dietary intervention (N=63), 6 months of daily peanut exposures (skin-roasted peanuts or peanut butter versus control butter with peanut oil) produced measurable changes in the plasma lipidome: linear mixed models identified 51 within-class fatty-acid (FA) sums responsive to peanut fat, concentrated in very long-chain saturated FA (VLCSFA)-containing lipids, particularly sphingolipids.

Key findings

  • The ARISTOTLE randomized intervention modified 51 within-class fatty-acid sums in plasma, predominantly affecting VLCSFA-containing lipids and especially sphingolipids.51 within-class FA sums modified
“ARISTOTLE randomly assigned 63 healthy young adults to 25 g/d skin-roasted peanuts, 32 g/d peanut butter, or 32 g/d control butter with peanut oil for 6 mo.”
What this piece can’t prove
  • Relatively small randomized sample (N=63) drawn from healthy young adults limits external generalizability.

2 further details could not be confirmed from the summary.

2secondary dataConstruct a peanut lipidomic signature (PeLS) from intervention-responsive lipids and test its association with incident type 2 diabetes (T2D) and cardiovascular disease (CVD) in EPIC-Potsdam case-cohort.secondary data: cross-study signature translation and case-cohort outcome analysisExpand

In plain English

Lipid features responsive to a 6-month peanut intervention in ARISTOTLE were pooled into a peanut lipidomic signature (PeLS) and applied to baseline plasma lipidomics in the EPIC-Potsdam case-cohort to test associations with incident type 2 diabetes (T2D) and cardiovascular disease (CVD).

Key findings

  • A peanut-derived lipidomic signature (PeLS), based on intervention-responsive lipids from ARISTOTLE, was associated with lower incident T2D risk in EPIC-Potsdam.HR 0.89 per 1-SD increase (95% CI: 0.80–0.99)
  • PeLS was not associated with incident CVD in EPIC-Potsdam.HR 1.01 per 1-SD increase (95% CI: 0.90–1.15)
“We integrated data from the clinical trial ARISTOTLE and the prospective, population-based ... EPIC-Potsdam cohort.”
What this piece can’t prove
  • PeLS was derived from intervention-responsive lipids in a small randomized trial (ARISTOTLE, n=63); transferability and potential overfitting to trial-specific changes are possible concerns.

2 further details could not be confirmed from the summary.

3secondary dataConstruct a peanut lipidomic signature (PeLS) from intervention-responsive lipids and test its association with incident type 2 diabetes (T2D) and cardiovascular disease (CVD) in EPIC-Potsdam case-cohort.Prospective case-cohort; multivariable Cox modelsExpand

In plain English

A peanut-derived lipidomic signature (PeLS), constructed from intervention-responsive plasma lipids, was measured at baseline in EPIC-Potsdam case-cohort samples and tested for association with incident type 2 diabetes (T2D) and cardiovascular disease (CVD) using multivariable Cox models. PeLS was modestly associated with lower T2D risk but not with CVD; mediation analysis identified BMI as a possible mediator of the T2D association (hypothesis-generating).

Key findings

  • Higher baseline PeLS was associated with a modestly lower risk of incident type 2 diabetes in EPIC-Potsdam.HR 0.89 per 1-SD increase in PeLS (95% CI: 0.80–0.99)
  • Baseline PeLS was not associated with incident cardiovascular disease in EPIC-Potsdam.HR 1.01 per 1-SD increase in PeLS (95% CI: 0.90–1.15)
“Multivariable Cox models were used to estimate hazard ratios (HRs) for PeLS and individual lipids with incident T2D and CVD.”
What this piece can’t prove
  • Observational association analysis in a case-cohort; potential for residual confounding despite multivariable adjustment (not detailed in abstract).
  • PeLS and lipids were measured at baseline only; temporal changes during follow-up not captured.
  • Mediation results were presented as hypothesis-generating and should be interpreted cautiously.

1 further detail could not be confirmed from the summary.

4secondary dataAssess (hypothesis-generating) mediation of the PeLS–T2D association by body mass index (BMI).secondary analysis (mediation)Expand

In plain English

In EPIC-Potsdam, the authors conducted a hypothesis-generating mediation analysis examining whether body mass index (BMI) mediates the association between a peanut-derived lipidomic signature (PeLS) and incident type 2 diabetes (T2D). They report that BMI was identified as a potential mediator, with a reported proportion explainable of 89% (95% CI: 57%, 100%). The mediation analysis details (specific model, covariates, and estimation approach) are not provided in the abstract.

Key findings

  • BMI was reported as a potential mediator of the association between the peanut lipidomic signature (PeLS) and incident type 2 diabetes in EPIC-Potsdam.Proportion explainable = 89% (95% CI: 57%, 100%)
“Hypothesis-generating mediation by body mass index (BMI) was assessed.”
What this piece can’t prove
  • Result framed as hypothesis-generating rather than confirmatory.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 30 candidate papers

And 24 more candidates considered.